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Abstract 
Acetaminophen (APAP) administration results in hepatotoxicity and hematotoxicity in cats. The response to three 
different treatments against APAP poisoning was evaluated. Free glutathione (GSH) (200mg/kg), niosomal GSH (14 
mg/kg) and free amino acids (180 mg/kg of N-acetylcysteine and 280 mg/kg of methionine) were administered to 
cats that were intoxicated with APAP (a single dose of 150 mg/kg, p.o.). Serum concentration of alanine 
aminotransferase (ALT) along with serum, liver and erythrocyte concentration of GSH and methemoglobin 
percentage were measured before and 4, 24 and 72 hours after APAP administration. Free GSH (200 mg/kg) and 
niosomal GSH (14 mg/kg) were effective in reducing hepatotoxicity and hematotoxicity in cats intoxicated with a 
dose of 150 mg/kg APAP. We conclude that both types of treatments can protect the liver and haemoglobin against 
oxidative stress in APAP intoxicated cats. Furthermore, our results showed that treatment with niosomal GSH 
represents an effective therapeutic approach for APAP poisoning. 
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Introduction 
Acetaminophen (APAP) is one of the most widely 
used analgesic and antipyretic in human medical 
practice (Mirochnitchenko et al., 1999). However, 
APAP is highly toxic to cats and dogs when 
administered at human doses. The common factor in 
APAP poisoning is the erroneous administration by 
the owner without prior consultation with the 
veterinarian. For this reason, APAP intoxication 
represents a common cause of feline and canine 
toxicoses reported to veterinary poison treatment 
centers (Jones et al., 1992; Allen, 2003).  
In particular, there is no safe dose of APAP for cats.  
Studies have shown that a dose of 50 to 100 mg/kg 
bodyweight of APAP is toxic to cats (Sellon, 2001).  
There is also evidence which indicates that a dose as 
low as 10 mg/kg bodyweight can produce signs of 
toxicity and lead to death (Aronson and Drobatz, 
1996). The pathways for APAP metabolism are via 
glucuronidation and sulfation, followed by renal 
excretion of the conjugates in most of the mammalian 
species (Davis el al., 1974; Savides et al., 1984).  
A small percentage of APAP is oxidized by 
cytochrome P450 enzymes (metabolic activation of 
APAP) to the highly reactive metabolite, N-acetyl-p-
benzoquinoneimine (NAPQI) (Davis et al., 1974). 
NAPQI binds to glutathione (GSH) and is excreted in 
the form of mercapturic acid conjugate (Davis et al., 
1974).  
The domestic cat (Felis catus) is extremely sensitive 
to the toxic effects of APAP for several reasons. One 
of the main reasons is slow and poor glucuronidation 
ability in this species.  Poor glucuronidation is due to 
UDP glucuronosyltransferase 1A6 (UGT1A6), the key 
isoenzyme responsible for APAP detoxification, being 
not expressed in the liver of cats.  
In the Felidae family, lack of UGT1A6 isoenzyme is 
the result of multiple inactivating mutations of the 
gene that encodes UGT1A6, rendering the species 
defective for APAP metabolism (Court and 
Greenblatt, 2000; Shrestha et al., 2011). Another 
reason for APAP toxicity is the limited capacity of the 
sulfation pathway in cats compared to other species 
(Savides et al., 1984). For both the reasons mentioned 
above, APAP persists in the blood and as a result, 
APAP is metabolized by cytochrome P-450 enzymes 
to the highly reactive metabolite NAPQI which further 
depletes the GSH reserves (Allen, 2003).  
Another detrimental effect of NAPQI is that it reacts 
with cellular proteins and affects mitochondrial 
respiration (early mitochondrial injury). NAPQI-
induced oxidative stress also leads to a delayed 
mitochondrial injury (Jaeschke et al., 2011) and cell 
death. Erythrocytes are the cells that are most 
susceptible to the toxic effects of NAPQI in the cats 
(McConkey et al., 2009).  
Two key components in erythrocytes are susceptible 
to NAPQI-induced oxidative injury: the iron in heme 
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and the sulfhydryl groups of the globulin chains. 
NAPQI causes the oxidation of ferrous iron (Fe2+) to 
ferric iron (Fe3+), which converts hemoglobin to 
methemoglobin (Richardson, 2000). In this regard, it 
is important to note that cats have a relative deficiency 
of methemoglobin reductase in erythrocytes. Thus, 
methemoglobinemia is a primary and prominent 
feature of APAP toxicity in this species.  
Another deleterious effect of NAPQI in cats is the 
oxidation of thiol groups of hemoglobin with the 
consequent production of large amounts of 
methemoglobin and Heinz bodies (Desnoyers, 2000). 
This particular reaction in cats has been attributed to 
the high numbers of sulfhydryl groups that are 
exposed on the surface of feline haemoglobin.  
Traditional treatment of APAP toxicity involves the 
administration of alternate sulfhydryl donors in order 
to inhibit the formation of the reactive metabolite 
(Savides et al., 1985). N-acetylcysteine (NAC) is the 
most widely used compound for the treatment of 
APAP toxicity (Polson and Lee, 2005). This 
compound protects against oxidative injury by 
providing cysteine groups for GSH biosynthesis and 
also by directly inactivating NAPQI via its sulfhydryl 
group (Corcoran and Wong, 1986).  
In contrast to NAC, GSH has not been used clinically 
in APAP poisoning because it is rapidly hydrolyzed 
and has a short plasma half-life ranging from 2 to 15 
minutes (Wendel and Jaeschke, 1982; Hong et al., 
2005; Saito et al., 2010). However, recent studies 
indicate that intravenous administration of GSH was 
effective in treating mice exhibiting APAP toxicity, 
because it causes an increase in the levels of hepatic 
GSH due to de novo synthesis from amino acids 
released by the hydrolysis of GSH (Knight et al., 
2002; Saito et al., 2010; Masubuchi et al., 2011). 
Niosomal GSH could be effective in the treatment of 
APAP intoxication. Encapsulation into vesicles 
protects the tripeptide from being hydrolysed and 
thereby permits a higher concentration to reach the 
liver. Niosomes (non–ionic surfactant vesicles) are 
nanovesicular drug delivery systems formed by self-
assembly of molecules of nonionic surfactant and 
cholesterol. The surfactants used and also the prepared 
niosomes are biodegradable, biocompatible and non-
immunogenic (Sankhyan and Pawar, 2012).  
These vesicles are used in the transport of active 
compounds in the form of drugs, genes or vaccine 
fractions.  Niosomes can modify the pharmacokinetics 
and bioavailability of the drugs (Baillie et al., 1985; 
Uchegbu and Florence, 1995). After intravenous 
administration, the biological behavior 
(pharmacokinetics, arrival at the site of action, 
therapeutic efficacy and adverse reactions) of the 
niosomes is controlled by a complex set of 
physicochemical and biological factors that include 
the size of the vesicles, shape and composition of the 
membrane, biochemical, anatomical and 
immunological barriers (Moghimi et al., 2012).  
Thus, not only the characteristics, but also the 
performance of the prepared niosomes can be 
exquisitely controlled by altering the composition, 
concentration of various additives, size, lamellarity 
and surface charge of vesicles (Khan et al., 2011). 
Studies show that the therapeutic efficacy of the drugs 
can be significantly improved by reducing the 
clearance rate, targeting to the specific site and by 
protecting the encapsulated drug (Sankhyan and 
Pawar, 2012).  
The purpose of this study was to compare the efficacy 
of NAC, free GSH and niosomal GSH in the treatment 
of APAP toxicity in cats.  
Material and Methods 
Drugs and reagents 
Reduced L-GSH, O-phthaldialdehyde (OPA), DL-
dithiothreitol (DTT), tris hydroxymethyl 
aminomethane and sodium tetraborato, dihexadecyl 
phosphate (DCP) were obtained from Sigma Aldrich 
(St Louis, USA). Sodium acetate was obtained from 
Farmitalia, Carlo Erba (Milano, Italy). Sodium 
dihydrogen phosphate monohydrate, cholesterol and 
chlorhydric acid were obtained from JT Baker 
(Xalostos, Mexico).  
Methanol and acetonitrile HPLC grade were obtained 
from JT Baker (Phillipsburg, USA). Metaphosphoric 
acid (MPA) was obtained from Riedel-de Haën 
(Seelze, German); ethylenediaminetetraacetic acid 
solution 0.342 mol/l (EDTA) was obtained from 
Wiener Lab, Argentina. APAP (®Paracetamol Raffo, 
1 g); ALT UV AA diagnostic kit (Wiener Lab, 
Argentina); hemoglobin standart (Wiener Lab, 
Argentina); potassium ferricyanide (Biopack, 
Argentina); potassium cyanide (Biopack, Argentina). 
Sorbitol monostearate (Span 60) was obtained from 
Fluka, Spain; polycarbonate membranes (Isopore) of 
0.8, 0.4 and 0.2 µm were obtained from Millipore. 
Saline Sodium Chloride 0.9% was obtained from 
Roux-Ocefa U (Argentina).  
Preparation of GSH niosomes 
Preparation of niosomes was carried out at ~65°C. It 
was essential to prepare the vesicles at a temperature 
above the gel-liquid transition temperature of span 60. 
Niosomes were prepared by hydration of melted 
surfactant/cholesterol/DCP (67.5: 27.5: 5) at 65°C in a 
50 ml beaker (Niemiec et al., 1995; Uchegbu and 
Vyas, 1998; Confalonieri et al., 2010). The non-ionic 
surfactant was melted using a magnetic stirrer with a 
heated plate (AREC, Velp Scientifica), once melted, 
cholesterol and DCP were added and the mixture was 
hydrated with a GSH solution in saline sodium 
chloride (5.4 M) by shaking with the magnetic stirrer 
for 60 min. Then the suspensions were processed for 3 
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min at 16,000 rpm (Ultraturrax T-25) and finally, 
sonicated for 3 minutes at 40 Khz power (Mod Testlab 
Ultrasound TBO10). Once this process was completed 
the suspensions were maintained at 65°C and 
manually extruded, five times each, successively 
through polycarbonate membranes (0.8, 0.4 and 0.2 
μm). 
Determination of GSH entrapment efficiency 
The removal of the unbound GSH from the vesicles 
was accomplished by ultracentrifugation at 150,000 g 
at 4°C for 90 minutes (Ultracentrifuge Sorvall Ultra 
Pro 80). The isolated pellets were washed twice, each 
with saline sodium chloride, and recentrifuged again 
for 1 hour. The supernatant was removed and the 
pellets were resuspended in the saline sodium chloride 
to obtain a total lipid concentration of 20 mM.  
The amount of entrapped GSH was determined after 
disruption of vesicles by lipid extraction method 
(Bligh and Dyer, 1959). The GSH incorporated into 
the niosomes was analysed by HPLC as described 
previously (Denzoin et al., 2008). Entrapment 
efficiency (E%) was expressed as a percentage of the 
total amount of GSH found in the disrupted vesicles. 
The entrapment efficiency of GSH is calculated as 
follows (Ruckmani et al., 2000):  
 
         
 m                     
       m           
       
 
Characterization of GSH niosomes 
Vesicles were characterised by optical and light 
polarized microscopy (Olympus BX40) for vesicle 
formation, agglutination and morphology. Samples of 
the niosomal formulations were examined under the 
optical microscope and were photographed at a 
magnification of 1000×. The size distribution and the 
polydispersivity index of the vesicles was determined 
using dynamic light scattering at 25°C with a 
scattering angle of 90° (Zetasizer Nano ZS, Malvern).  
Animals 
Sixteen healthy adult, domestic shorthaired cats were 
used for this study. The mean age of the cats was 3.2 
years old (range 2-5 years), and the average body 
weight was 3.84 ± 0.69 kg.  
The cats were fed with cat food for adult maintenance 
(Association of American Feed Control Officials) on 
an ad libitum basis from 8:00 am to 6:00 pm daily. 
Water was also provided ad libitum. The animals were 
kept fasting for 12 hours prior to starting the 
experimental protocol. This study was performed 
according to the standards established by the Animal 
Welfare Commission of Faculty of Veterinary 
Science. 
Experimental protocol 
The animals were divided in four groups containing 
four animals each (Groups I, II, III and IV) and 
anesthetized using a combination of ketamine (15 
mg/kg) and xylazine (0.5 mg/kg). An intravenous 
catheter (Abbocath G18) was placed in the jugular 
vein to facilitate administration of drugs used for the 
treatment and an intravenous catheter (Abbocath G22) 
was placed in antebrachial cephalic vein for sampling 
the blood.  
After recovery from the anaesthesia, the animals were 
transferred back to their cages. Group I (control) 
received a single dose of 150 mg/kg of APAP 
administrated orally. This dose was established by us 
in a previous work (Castro, 2001). Group II received a 
single oral dose of 150 mg/kg of APAP and a dose of 
GSH 200 mg/kg (mouse dose according to Wendel 
and Jaeschke (1982)) solubilized in 100 ml of 
physiological saline solution by intravenous infusion.  
Group III received a single oral dose of 150 mg/kg 
APAP and a dose of niosomal GSH 14 mg/kg 
solubilized in 100 ml of physiological saline solution 
by intravenous infusion. This was the maximum dose 
of GSH that could be encapsulated into the niosomes. 
Group IV received a single oral dose of 150 mg/kg of 
APAP and an oral dose of 180 mg/kg of N-
acetylcysteine and 280 mg/kg of methionine dissolved 
in 10 ml of physiological saline solution of sodium 
chloride 0.9% using a probe K30 tube. 
Blood and liver sampling 
Blood and liver samples were collected from all the 
animals at 0, 4, 24 and 72 hours after dosing. Blood 
samples (5 ml) were collected and immediately placed 
into refrigerated tubes containing EDTA as an 
anticoagulant.  
Three liver biopsies of each animal were collected 
using Menghini's technique (Menghini, 1958) using 
local anaesthesia. The liver biopsies were placed in 
chilled physiological saline solution. The percentage 
of methemoglobin was determined by colorimetry 
(Sato, 2005).  
Levels of Alanine animotransferase (ALT) was 
measured at 37°C in spectrophotometer (Pharmacia 
Ultrospec III) using the optimized method UV 
(Wiener Lab). GSH concentrations in plasma, 
erythrocytes and liver were determined according to 
the method previously described (Denzoin et al., 
2008). Liver protein concentration was determined 
using the Lowry et al. (1951) method.  
Statistical analysis  
A completely randomized design was established with 
measurements repeated over time, using a linear 
mixed model with an autoregressive correlation 
structure of order 1 (InfoStat 2011p version). 
Results 
GSH niosomes 
The GSH entrapment efficiency of niosomes was 49.9 
%. Photomicrographs of the GSH niosomes are shown 
in Fig. 1.  
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The GSH niosomes were spherical in shape. No 
aggregates were observed. The mean particle 
diameters were 422 nm. 
 
 
Fig. 1. Photomicrograph of GSH loaded niosomes composed 
of Spam 60/cholesterol/DCP (67.5: 27.5: 5). The arrows 
show the vesicles.  
 
Clinical signs 
Group I and Group IV exhibited clinical 
manifestations of APAP acute intoxication.  Clinical 
characteristics included cyanosis and tachypnea 
between 2 and 6 hours post treatment followed by 
anorexia and depression between 24 and 72 hours. 
Groups II and III showed only anorexia. No deaths 
were recorded during the entire experimental protocol.  
Group IV showed no significant differences in ALT 
activity (p>0.05) compared to Group I. On the other 
hand, Group II and Group III showed a small but 
significant (p<0.05) increase in ALT levels when 
compared to Groups I and IV (Fig. 2). 
Fig. 2. ALT levels in the treated groups. Group I: 150 mg/kg 
of APAP. Group II 150 mg/kg of APAPand GSH 200 
mg/kg. Group III 150 mg/kg of APAPand niosomal GSH 
(14 mg/kg). Group IV 150 mg/kg of APAP, 180 mg/kg of 
N-acetylcysteine and 280 mg/kg of methionine. The square 
indicates the basal values. Different letters indicate 
significant differences between the groups (p<0.05). 
No significant differences in methemoglobin levels 
were observed between Groups I and IV. Groups II 
and III showed significant differences with respect to 
Groups I and IV (Fig. 3). Although no significant 
differences were observed between groups treated 
with free GSH and niosomal GSH, the group treated 
with free GSH (group II) showed lower 
methemoglobin formation than the group treated with 
niosomal GSH (group III). 
 
Fig. 3. Methemoglobin percent in the treated groups. Group 
I: 150 mg/kg of APAP. Group II 150 mg/kg of APAPand 
GSH 200 mg/kg. Group III 150 mg/kg of APAPand 
niosomal GSH (14 mg/kg). Group IV 150 mg/kg of APAP, 
180 mg/kg of N-acetylcysteine and 280 mg/kg of 
methionine .The square indicates basal values. Different 
letters indicate significant differences between the groups   
(p<0.05). 
 
There was a significant increase in plasma 
concentration of GSH at 4 hours post treatment in 
groups II and III when compared to the control group 
(group I). Likewise, significant differences in plasma 
GSH concentrations were found between groups II 
and III (Fig. 4). 
Liver GSH concentration decreased at 4 hours post 
treatment in groups I, II and IV, while group III 
(treated with niosomal GSH) showed an increase of 
GSH liver concentration at this time. In Groups II and 
III liver GSH concentration remained elevated above 
the baseline at 24 and 72 hours (Fig. 5). 
Group I showed a significant decrease in GSH 
concentration in the erythrocyte, which remained 
below the basal levels at 72 hours (Fig. 6) when 
compared to groups II, III and IV. 
Discussion 
Clinical symptoms of APAP intoxication in cats 
include rapid and significant methemoglobin 
formation (Nash et al., 1984). Furthermore, oxidation 
of hemoglobin leads to the denaturation of 
hemoglobin whose precipitation results in Heinz body 
formation and hemolytic anemia (Nash et al., 1984; 
McConkey et al., 2009). Methemoglobin and 
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hemolytic anemia result in respiratory distress, 
depression, and weakness that can lead to the death of 
the animal even prior to the development of liver 
toxicity.  
GSH treatment at 200 mg/kg by intravenous infusion 
and treatment with niosomal GSH at 14mg/kg by 
intravenous infusion were found to be effective in 
decreasing the levels of methemoglobin formation and 
hepatotoxic effects of APAP poisoning (Fig. 2 and 3). 
 
 
 
Fig. 4. Plasmatic GSH concentrations in the treated groups. 
Group I: 150 mg/kg of APAP. Group II 150 mg/kg of 
APAPand GSH 200 mg/kg. Group III 150 mg/kg of 
APAPand niosomal GSH (14 mg/kg). Group IV 150 mg/kg 
of APAP, 180 mg/kg of N-acetylcysteine and 280 mg/kg of 
methionine .The square indicates basal values. Different 
letters indicate significant differences between groups 
(p<0.05). 
 
 
Fig. 5. Liver GSH concentrations in the treated groups. 
Group I: 150 mg/kg of APAP. Group II 150 mg/kg of 
APAPand GSH 200 mg/kg. Group III 150 mg/kg of 
APAPand niosomal GSH (14 mg/kg). Group IV 150 mg/kg 
of APAP, 180 mg/kg of N-acetylcysteine and 280 mg/kg of 
methionine .The square indicates basal values. Different 
letters indicate significant differences between the groups 
(p<0.05). 
 
 
 
Fig. 6. GSH concentration in erythrocytes in the treated 
groups. Group I: 150 mg/kg of APAP. Group II 150 mg/kg 
of APAP and GSH 200 mg/kg. Group III 150 mg/kg of 
APAPand niosomal GSH (14 mg/kg). Group IV 150 mg/kg 
of APAP, 180 mg/kg of N-acetylcysteine and 280 mg/kg of 
methionine .The square indicates basal values. Different 
letters indicate significant differences between the groups (p 
<0.05). 
 
Treatment with a single oral dose of N-acetyl cysteine 
and methionine was not effective and did not show 
any significant differences when compared to the 
control group (Fig. 2 and 3). This treatment therefore 
would not be effective against APAP intoxication at a 
dose of 150 mg/kg. Groups II and III showed a 
decreased formation of methemoglobin. Both groups 
showed significant differences from group I and group 
IV (Fig. 3).  
The percentage of methemoglobin was lower in the 
group that was treated with free GSH (group II). The 
formation of methemoglobin during intoxication with 
APAP is a distinctive feature of this poisoning in both 
dogs and cats (MacNaughton, 2003). Methemoglobin 
formation occurs by the reaction of NAPQI with the 
thiol-reactive groups of the hemoglobin molecule 
(Nash et al., 1984; Savides et al., 1984). The high 
GSH concentration found in the liver of both species 
could inactivate NAPQI formed in this organ after 
APAP administration and thus would reduce the 
formation of methemoglobin. Additionally, elevated 
GSH plasma concentrations found at 4 hours post 
treatment in groups II and III could inactivate NAPQI 
in plasma, and contribute to reduce methemoglobin 
formation. Although NAPQI has been proposed as the 
molecule responsible for the formation of 
methemoglobin by most authors, McConkey et al. 
(2009) underestimate the importance of NAPQI in the 
formation of methemoglobin. They propose that the 
metabolite para-aminophenol, which is co-oxidized 
with the hemoglobin molecule, is more important than 
NAPQI. However, it is important to note that both the 
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metabolites (NAPQI and para-aminophenol) are 
inactivated by GSH (McConkey et al., 2009).  
The hepato-protective effect of GSH in groups II and 
III would be related to an increase in the GSH hepatic 
concentration in both groups after treatment. The 
GSH-induced mechanism of hepatoprotection 
involves improving the capacity of the hepatocytes to 
inactivate NAPQI, avoiding the covalent modification 
of cellular proteins and blocking the initiation of 
APAP toxicity (Corcoran and Wong, 1986). Free GSH 
administered intravenously is rapidly degraded by the 
  g  s  h   c    i   h    zym  γ-glutamyl 
    s    i  s  (γGT). The amino acids released by 
GSH hydrolysis are absorbed by hepatocytes and 
subsequently utilized for de novo GSH synthesis 
(Saito et al., 2010). APAP poisoning leads to 
decreased hepatic concentrations of GSH.  
Accordingly, treatment with GSH would be an 
effective solution because it provides the amino acids 
that contribute to restoration of liver GSH 
concentrations (Saito et al., 2010; Masubuchi et al., 
2011), and inactivate the NAPQI formed during the 
metabolic phase of APAP intoxication.  
In addition to the hepatoprotective effect of GSH in 
the metabolic phase of APAP intoxication, there 
would also be an effect of the treatment during the 
post metabolic phase. The covalent binding of NAPQI 
to mitochondrial proteins is a critical point that 
connected the metabolic phase of APAP toxicity to 
mitochondrial dysfunction and initiates the post 
metabolic phase of intoxication (Jaeschke et al., 
2011).  
This mitochondrial dysfunction leads to inhibition of 
mitochondrial respiration with the consequent 
formation of reactive oxygen species and formation of 
peroxynitrite in the mitochondrial matrix –an effect 
that consumes mitochondrial GSH (Jaeschke et al., 
2011).  
The elevated GSH liver concentrations observed in the 
group treated with free GSH (group II) would help to 
accelerate the restoration of mitochondrial GSH levels 
and inactivate the reactive species formed at this stage, 
thereby limiting hepatocellular necrosis. These effects 
are associated with a smaller increase in ALT levels in 
group II when compared to group I. 
Hepatoprotective effects were observed in the group 
treated with niosomal GSH (group III). While the 
results between groups II and III showed no 
significant differences, ALT activities were lower in 
the group treated with niosomes (group III) when 
compared to the group treated with free GSH (group 
II).  
The group treated with niosomal GSH had a marked 
increase in hepatic GSH concentration which was 
significantly different from all other treatments. This 
finding could be related to the selective accumulation 
of niosomal GSH in the liver (Uchegbu and Florence, 
1995; Hashim et al., 2010).  
The niosomal vesicles have a preferential passive 
targeting in the liver (Azmin et al., 1985; Baillie et al., 
1985; Uchegbu and Florence, 1995). After intravenous 
administration, the vesicles of a size greater than 200 
nm are rapidly removed from circulation because, 
after opsonisation, niosomes are recognized and 
phagocytosed by Kupffer cells of the liver (Ishida et 
al., 2002; Mozafari, 2006). Vesicles of 400 nm can 
also access the hepatocytes depending on the lipid 
composition and their membrane electric charge 
(Romero et al., 1999). 
Group IV (treated with a combination of amino acids 
methionine 180mg/kg and N- acetylcysteine 280 mg / 
kg) showed no significant differences respect to the 
group I (control). Several authors suggest the use of 
N-acetylcysteine (NAC) for the treatment of APAP 
intoxication in cats (Gaunt et al., 1981; Savides et al., 
1985) and NAC is also used for the treatment of 
poisoning in humans (Shen et al., 2011). Thus, our 
results do not concur with previously published data. 
One major reason for the observed discrepancy may 
be related to the differences in the dosing schedule. 
Gaunt et al. (1981) used an oral dosing regimen at 200 
mg/kg of NAC every two hours in cats that were 
intoxicated with 145 mg/kg of APAP and observed 
significant differences in the formation of 
methemoglobin respect to the control and found no 
increase in plasmatic ALT activity.  
Savides et al. (1985), using oral and intravenous doses 
of NAC in animals treated with 120 mg/kg of APAP, 
found both routes of the treatment to be effective, 
reporting a decrease in the formation of 
methemoglobin and increased erythrocyte GSH 
concentration. In a more recent report, Avizeh et al. 
(2010) treated a group of cats with a single dose of 
NAC (100 mg/kg) along with the administration of 
150 mg/kg of APAP and their results agree with those 
obtained by Gaunt et al. (1981). 
In conclusion, our results have shown that both free 
GSH (200 mg/kg) and niosomal GSH (14 mg/kg) 
treatments were highly effective in reducing both 
hepatotoxicity and hematotoxicity in cats that were 
intoxicated with a dose of 150 mg/kg APAP. 
Niosomes are a novel drug delivery system which 
offers advantages over other conventional vesicular 
delivery systems.   
Our results show that treatment with niosomal GSH 
represents an effective therapeutic approach for APAP 
poisoning. Our results were obtained despite using a 
lower dose of GSH. This clearly demonstrates that the 
encapsulated drug is selectively transported to the 
liver.  
Our findings can be of immense help in the treatment 
of pathophysiological conditions that result in 
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oxidative stress in the liver. From our work emerges 
the potential for the development of a combined 
therapy that employs both niosomal and free GSH. 
Our results suggest that this therapy is more promising 
than those currently used for the treatment of APAP-
induced toxicity. 
___________________________________________ 
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